Patients with schizophrenia, psychosis, and other neuropsychiatric conditions have limited treatment options that often require frequent dosing, cause undesirable side effects, or lack rapid onset, leading to poor adherence and suboptimal outcomes.

Terran Biosciences develops next‑generation therapeutics that combine novel prodrug formulations, selective serotonin 2A antagonists, and psychedelic compounds to address these gaps. By creating once‑daily oral doses and long‑acting injectable versions of a xanomeline‑trospium prodrug (TerXT), the company aims to improve dosing convenience and reduce relapse risk. Its selective 5‑HT2A antagonists (eplivanserin and volinanserin) are being evaluated as monotherapies and in fixed‑dose combinations with psychedelics to mitigate hallucinations while preserving therapeutic benefit. Terran also leverages an AI‑enabled drug design engine and a GMP manufacturing platform to accelerate discovery of non‑hallucinogenic psychoplastogens and other neuroactive agents. The integrated approach seeks to expand the therapeutic arsenal for schizophrenia, Parkinson’s psychosis, and emerging psychedelic‑based treatments.

Prodrug technology enabling once‑daily oral tablets and multi‑month injectable formulations for schizophrenia

Fixed‑dose combinations of selective 5‑HT2A antagonists with psychedelic agents to control hallucinations

AI‑driven medicinal chemistry platform that designs novel compounds, synthetic routes, and labeled analogs with optimized pharmacokinetics

GMP‑compliant manufacturing of a broad portfolio of psychedelics, empathogens, and non‑hallucinogenic psychoplastogens

Development of deuterated volinanserin and other next‑generation serotonergic agents with reduced off‑target liability

Primary customers are pharmaceutical partners, clinical research organizations, and treatment centers focused on schizophrenia, Parkinson’s disease psychosis, and psychedelic‑assisted therapies.